Foghorn Therapeutics Q2 net loss $29.5M; cash $284.3M; AML combo study starting Q3 2023

Foghorn Therapeutics Inc.

2023-Q2 EPS reported -$1.43 revenue$10,908,000

Net loss of $29.5M for Q2 2023 vs $27.3M in Q2 2022.
Cash, cash equivalents & marketable securities of $284.3M, providing runway into H2 2025.
Collaboration revenue $5.6M (up from $4.5M YoY), primarily from Lilly agreement.
FHD-286 combination study in AML to begin Q3 2023 after resolving clinical hold.
Pipeline advancing: selective BRM, ARID1B, EP300, CBP programs toward IND; six new INDs targeted in 4 years.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $5.6 million, net income $29.5 million.

Period: the quarter ended June 30, 2023
Revenue: $5.6 million
Net income: $29.5 million
Result: reported results

Exact text from the filing

Collaboration revenue was $5.6 million for the three months ended June 30, 2023, compared to $4.5 million for the three months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-027398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.